Navigation Links
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
Date:5/16/2012

data, 100% and 89% of vaccinated subjects demonstrated high-titered binding antibody responses against the more common Clade 1 A/Vietnam/1203/04 and Clade 2 A/Indo/5/05 strains, respectively, demonstrating vaccine-specific immune activation.

We also tested the vaccine's ability to generate protective HAI responses against six distinct H5N1 virus strains (Clades 0, 1, 2.1, 2.2, 2.3.2 and 2.3.4), representing all major genetic branches of the H5N1 genetic tree. Of the 17 subjects who completed the full immunization regimen:

  • Eight of 17 (47%) immunized subjects had an HAI titer of 1:40 or higher against at least one of the tested H5N1 viruses.
  • Twelve of 17 (71%) vaccinated subjects had an HAI titer of 1:20 or higher against at least one H5N1 strain.
  • Seven of 17 (41%) had an HAI titer of 1:40 or higher against the Clade 2.2 A/Turkey/1/05 strain.
  • Five of 17 vaccinated subjects (29%) displayed an HAI titer of 1:20 or higher against at least three different H5N1 viruses tested.
  • In an unprecedented result, two vaccinated subjects demonstrated an HAI titer of 1:20 or higher against all six strains tested.

Hemagglutination inhibition (HAI) measurements from the blood of a vaccinated subject are used to assess the generation of protective HA antibody responses generated by a vaccine. All HAI titer data are presented in geometric mean titers (GMT). Generating an HAI titer of 1:20 is generally regarded as a positive response to the vaccine; a titer of 1:40 or higher in the blood of vaccinated subjects is generally associated with protection against seasonal influenza viruses and has been observed in multiple subtypes.

Inovio is advancing its universal influenza vaccine strategy with a second Phase I influenza vaccine study. This trial is assessing Inovio's INO-3510 multi-subtype SynCon® vaccine consisting of the H5N1 and H1N1 subtypes, delivered exclusively using
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals to Present at SPI 2012
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. Inovio Receives U.S. Patent for SynCon® H1N1 Influenza Universal Vaccine
5. Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
6. Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference
7. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
8. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
9. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
10. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
11. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... QTinno(TM) - proves the ability to automatically measure QT ... intervals in even challenging samples, ... Board: NWCI) a cardiac diagnostic and services company, today,revealed the ... Study"). The study was led by an independent industry leading,cardiac ...
... Battles Highest Rate of TB Infection in U.S., ... highest,rate of tuberculosis (TB) in the U.S., with recurrent ... most recent study on,homelessness and TB by Harvard Medical ... in San Francisco. To address this health care,crisis, St. ...
Cached Medicine Technology:NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5National Healthcare for Homeless Day: August 13th, 2008 2
(Date:8/22/2014)... UT (PRWEB) August 22, 2014 Today, ... a new guide on Account-Based Health Plans. , According ... (ABHPs) as a strategy to lower the cost of ... types of medical spending accounts, however, can be confusing. ... chart to learn the four main types of ABHPs. ...
(Date:8/22/2014)... August 23, 2014 Top 10 ... famous web hosting companies and highly recommended FatCow ... , The manager of Top 10 Best SEO ... good dedicated server hosting supplier. Actually, these companies ... server speed and customer support. People can get ...
(Date:8/22/2014)... Recently, UWDress.com, a leading online supplier of ... new range of empire bridesmaid dresses to its ... a summer promotion for these high quality items. All of ... to 75 percent off. , The company’s new items ... efficient assistance on its website. It is true that all ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... Japantown Dental is excited to announce that ... Air polishing is a technique used to remove external ... be caused by a number of factors, which are ... External stains include coffee, wine, tea, smoking and chewing ... such as tetracycline, and direct trauma to the tooth. ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Japantown Dental Introduces Air Polishing 2
... ROCHESTER, N.Y., Nov. 26 As one of the ... considering the most sweeping,changes to that state,s health care ... the Christian Science church, called on,state leaders to bring ... access to effective health care by including spiritual,care., ...
... The Wackenhut,Corporation, the leading security services provider, announced ... its employee medical and dental,insurance plans significantly for ... that Wackenhut,s focus on employee welfare is a,primary ... Mercer, released an overview of,its most recent annual ...
... FLEX ),today announced that it will report third quarter ... call, hosted by Flextronics,s senior,management, will be held at ... Company for its third quarter ended December 31, 2007., ... Internet and may be,accessed by logging on to the ...
... with the devices aren,t prone to accidents , , MONDAY, ... implanted in people for instant correction of abnormal heartbeats ... researchers report. , "What this confirms is what we ... risk in this population," said study lead author Dr. ...
... Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, PHILADELPHIA and ... and Merck & Co., Inc.,Whitehouse Station, NJ, USA (Merck), announced ... marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK will have ...
... Older and newer medicine together often bring relief, study ... an older synthetic drug with a newer, "biologic" medication ... tenderness of rheumatoid arthritis, a new study finds. , ... newer drugs are not better than older ones when ...
Cached Medicine News:Health News:Wackenhut Enhances Health Insurance Plans Without Raising Costs 2Health News:Flextronics to Report Third Quarter Results 2Health News:Defibrillators Not Dangerous While Driving 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: